|
|
Article: Romark Laboratories Announces Clinical Study Evaluating Alinia(R) for Treatment of Crohn's Disease.
- Article from:
- PR Newswire
- Article date:
- August 24, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Unique Mechanism Offers Innovative Approach to Treating Crohn's Disease
TAMPA, Fla., Aug. 24 /PRNewswire/ -- Romark Laboratories has begun enrolling patients in a clinical trial evaluating Alinia (nitazoxanide) for treatment of mild to moderate active Crohn's disease in adults.
The randomized, double-blind trial will compare the efficacy and safety of Alinia to that of a placebo. Alinia will be administered orally as a single 500 mg tablet two times per day. The study will be conducted in multiple centers in the United States.
"We believe nitazoxanide presents a unique and innovative approach to treating Crohn's disease," said Jean-Francois ...